152,970 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, HoldingsChannel.com reports. The firm bought 152,970 shares of the biopharmaceutical company’s stock, valued at approximately $41,305,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth $27,000. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $28,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares during the period. Finally, Colonial Trust Co SC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 0.3%

Shares of ALNY opened at $452.00 on Friday. The company has a market cap of $59.25 billion, a price-to-earnings ratio of -183.00 and a beta of 0.32. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a fifty day moving average price of $387.47 and a two-hundred day moving average price of $309.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same period last year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ALNY shares. Piper Sandler upped their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, Oppenheimer upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective for the company in a research report on Monday, August 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $417.38.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the transaction, the executive vice president directly owned 22,719 shares in the company, valued at $10,297,841.13. This trade represents a 5.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 6,979 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33. Following the sale, the chief executive officer directly owned 56,221 shares in the company, valued at $25,483,292.67. The trade was a 11.04% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 57,594 shares of company stock worth $25,551,456. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.